Deargen Announces New Model of Optimizing Drug Candidate Molecules With Enhanced Performance by Nearly Double Compared to Existing Models

Published: Apr 09, 2021
 
At ACM CHIL 2021, the company presented study results on a model of simultaneously optimizing multiple properties of molecules with enhanced performance by nearly double compared to models of Google-Stanford University and MIT
It can be used for optimizing molecule design in pre-clinical and clinical stage
 
SEOUL, South Korea--(BUSINESS WIRE)-- Deargen, an artificial intelligence (AI)-based drug discovery and development biotech company, announced on April 9 that it presented study results on controlled molecule generator (CMG) technology at the ACM Conference on Health, Inference and Learning (ACM CHIL) 2021. The CMG technology can optimize multiple properties of molecules simultaneously.

Related Keywords

New York ,United States ,Seoul ,Soult Ukpyolsi ,South Korea ,Bonggeun Shin ,Kilsoo Kang ,Conference On Health ,Association For Computing Machinery ,Computing Machinery ,Chief Artificial Intelligence Officer ,புதியது யார்க் ,ஒன்றுபட்டது மாநிலங்களில் ,சியோல் ,தெற்கு கொரியா ,மாநாடு ஆன் ஆரோக்கியம் ,சங்கம் க்கு கணினி இயந்திரங்கள் ,கணினி இயந்திரங்கள் ,தலைமை செயற்கை உளவுத்துறை அதிகாரி ,